These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 26507107)

  • 1. Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury?
    Slizgi JR; Lu Y; Brouwer KR; St Claire RL; Freeman KM; Pan M; Brock WJ; Brouwer KL
    Toxicol Sci; 2016 Jan; 149(1):237-50. PubMed ID: 26507107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors.
    Woodhead JL; Brock WJ; Roth SE; Shoaf SE; Brouwer KL; Church R; Grammatopoulos TN; Stiles L; Siler SQ; Howell BA; Mosedale M; Watkins PB; Shoda LK
    Toxicol Sci; 2017 Jan; 155(1):61-74. PubMed ID: 27655350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocellular Disposition and Transporter Interactions with Tolvaptan and Metabolites in Sandwich-Cultured Human Hepatocytes.
    Lu Y; Slizgi JR; Brouwer KR; Claire RL; Freeman KM; Pan M; Brock WJ; Brouwer KL
    Drug Metab Dispos; 2016 Jun; 44(6):867-70. PubMed ID: 27013400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative Systems Toxicology Modeling Predicts that Reduced Biliary Efflux Contributes to Tolvaptan Hepatotoxicity.
    Beaudoin JJ; Brock WJ; Watkins PB; Brouwer KLR
    Clin Pharmacol Ther; 2021 Feb; 109(2):433-442. PubMed ID: 32748396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury.
    Li X; Zhong K; Guo Z; Zhong D; Chen X
    Drug Metab Dispos; 2015 Nov; 43(11):1751-9. PubMed ID: 26276582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease.
    Beaudoin JJ; Bezençon J; Cao Y; Mizuno K; Roth SE; Brock WJ; Brouwer KLR
    Drug Metab Dispos; 2019 Feb; 47(2):155-163. PubMed ID: 30504136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Species differences in hepatobiliary disposition of taurocholic acid in human and rat sandwich-cultured hepatocytes: implications for drug-induced liver injury.
    Yang K; Pfeifer ND; Köck K; Brouwer KL
    J Pharmacol Exp Ther; 2015 May; 353(2):415-23. PubMed ID: 25711339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nimesulide and 4'-Hydroxynimesulide as Bile Acid Transporters Inhibitors Are Contributory Factors for Drug-Induced Cholestasis.
    Zhou L; Pang X; Jiang J; Zhong D; Chen X
    Drug Metab Dispos; 2017 May; 45(5):441-448. PubMed ID: 28202577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Two-Tiered In Vitro Approach to De-Risk Drug Candidates for Potential Bile Salt Export Pump Inhibition Liabilities in Drug Discovery.
    Hafey MJ; Houle R; Tanis KQ; Knemeyer I; Shang J; Chen Q; Baudy A; Monroe J; Sistare FD; Evers R
    Drug Metab Dispos; 2020 Nov; 48(11):1147-1160. PubMed ID: 32943412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Hepatobiliary Transport Activity by the Antibacterial Agent Fusidic Acid: Insights into Factors Contributing to Conjugated Hyperbilirubinemia/Cholestasis.
    Lapham K; Novak J; Marroquin LD; Swiss R; Qin S; Strock CJ; Scialis R; Aleo MD; Schroeter T; Eng H; Rodrigues AD; Kalgutkar AS
    Chem Res Toxicol; 2016 Oct; 29(10):1778-1788. PubMed ID: 27676153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.
    Hartman JC; Brouwer K; Mandagere A; Melvin L; Gorczynski R
    Can J Physiol Pharmacol; 2010 Jun; 88(6):682-91. PubMed ID: 20628435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report.
    Pellegrino AM; Annicchiarico Petruzzelli L; Riccio E; Pisani A
    BMC Nephrol; 2019 Nov; 20(1):426. PubMed ID: 31752750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4.
    Köck K; Ferslew BC; Netterberg I; Yang K; Urban TJ; Swaan PW; Stewart PW; Brouwer KL
    Drug Metab Dispos; 2014 Apr; 42(4):665-74. PubMed ID: 24154606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database.
    Watkins PB; Lewis JH; Kaplowitz N; Alpers DH; Blais JD; Smotzer DM; Krasa H; Ouyang J; Torres VE; Czerwiec FS; Zimmer CA
    Drug Saf; 2015 Nov; 38(11):1103-13. PubMed ID: 26188764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Morgan RE; van Staden CJ; Chen Y; Kalyanaraman N; Kalanzi J; Dunn RT; Afshari CA; Hamadeh HK
    Toxicol Sci; 2013 Nov; 136(1):216-41. PubMed ID: 23956101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of tolvaptan for autosomal dominant polycystic kidney disease.
    Baur BP; Meaney CJ
    Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.
    Irazabal MV; Torres VE; Hogan MC; Glockner J; King BF; Ofstie TG; Krasa HB; Ouyang J; Czerwiec FS
    Kidney Int; 2011 Aug; 80(3):295-301. PubMed ID: 21544064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials.
    Alpers DH; Lewis JH; Hunt CM; Freston JW; Torres VE; Li H; Wang W; Hoke ME; Roth SE; Westcott-Baker L; Estilo A
    Am J Kidney Dis; 2023 Mar; 81(3):281-293.e1. PubMed ID: 36191725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.